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Short	title:	Double-hit	CLL	with	17p	deletion	and	8q24	gain	
	Abstract	
Chronic	lymphocytic	leukemia	(CLL)	with	17p	deletion	(17p-)	is	associated	with	a	lack	of	response	to	
standard	 treatment	 and	 thus	 the	 worst	 possible	 clinical	 outcome.	 Various	 chromosomal	
abnormalities	 (including	 unbalanced	 translocations,	 deletions,	 ring	 chromosomes	 and	
isochromosomes)	 result	 in	 the	 loss	 of	 17p	 and	 one	 copy	 of	 the	 TP53	 gene.	 The	 objective	 of	 the	
present	study	was	to	determine	whether	the	type	of	chromosomal	abnormality	leading	to	17p-	and	
the	additional	aberrations	influenced	the	prognosis	in	a	series	of	195	patients	with	17p-CLL.	Loss	of	
17p	 resulted	primarily	 from	an	unbalanced	 translocation	 (70%)	with	 several	 chromosome	partners	
(the	most	 frequent	 being	 chromosome	18q),	 followed	by	 deletion	 17p	 (23%),	monosomy	17	 (8%),	
isochromosome	 17q	 [i(17q)]	 (5%)	 and	 a	 ring	 chromosome	 17	 (2%).	 In	 a	 univariate	 analysis,	
monosomy	17,	a	highly	complex	karyotype	(>5	abnormalities),	and	8q24	gain	were	associated	with	
poor	treatment-free	survival,	and	i(17q)	(p=0.04),	unbalanced	translocations	(p=0.03)	and	8q24	gain	
(p=0.001)	 were	 significantly	 associated	 with	 poor	 overall	 survival.	 In	 a	 multivariate	 analysis,	 8q24	
gain	 remained	 a	 significant	 predictor	 of	 poor	 overall	 survival.	We	 conclude	 that	 17p	 deletion	 and	
8q24	gain	have	a	synergistic	 impact	on	outcome,	and	so	patients	with	this	“double-hit”	CLL	have	a	
particularly	 poor	 prognosis.	 Systematic,	 targeting	 screening	 for	 8q24	 gain	 should	 therefore	 be	
considered	in	cases	of	17p-	CLL.	
	
Keywords	
chronic	lymphocytic	leukemia	
17p	deletion	
prognosis	
8q24	gain	
isochromosome	17q	
	 	
Introduction	
	
Chronic	 lymphocytic	 leukemia	 (CLL),	 the	 most	 common	 leukemia	 in	 adults,	 has	 a	 highly	 variable	
course,	 reflecting	 its	 biological	 heterogeneity.	 Many	 patients	 do	 not	 require	 treatment	 for	 years,	
whereas	 others	 exhibit	 aggressive	 disease,	 do	 not	 respond	 to	 treatment,	 and	 thus	 have	 a	 poor	
prognosis.	 Chromosomal	 abnormalities	 (including	deletions	of	 11q,	 13q	or	 17p	 (17p-),	 and	 trisomy	
12)	 are	 present	 in	 about	 80%	 of	 cases	 of	 CLL.	 Fluorescence	 in	 situ	 hybridization	 (FISH)	 is	 used	 to	
routinely	 screen	 for	 these	 chromosomal	 abnormalities	 [1].	 Patients	 with	 17p-	 CLL	 have	 the	 worst	
clinical	 outcomes,	 and	 the	 shortest	 progression-free	 and	 overall	 survival	 (OS)	 times	 [2].	 The	 17p	
deletion	 is	 found	 in	 10%	 or	 less	 of	 patients	 with	 CLL	 but	 in	 up	 to	 40%	 of	 relapsed	 or	 treatment-
refractory	patients.	Loss	of	the	short	arm	of	the	chromosome	17	results	from	various	chromosomal	
abnormalities,	 including	 unbalanced	 translocations,	 deletions,	 ring	 chromosomes	 and	
isochromosomes	 [3].	All	 these	 aberrations	 lead	 to	 the	 loss	of	 one	 copy	of	 the	TP53	 gene,	 and	 the	
remaining	allele	 is	mutated	 in	most	 instances. Furthermore,	17p-	 is	often	associated	with	genomic	
complexity	as	detected	with	conventional	karyotyping	or	genomic	microarrays	[4,	5].	
The	dismal	prognosis	for	patients	with	17p-	CLL	is	mainly	due	to	a	lack	of	response	to	conventional	
treatments.	In	keeping	with	the	role	of	TP53	as	a	pivotal	regulator	of	the	DNA	response	pathway,	loss	
of	 this	 gene	 is	 associated	 with	 resistance	 to	 DNA-damaging	 agents	 (e.g.	 fludarabine	 and	
cyclophosphamide).	 Recently,	 new	 drugs	 targeting	 the	 B-cell	 receptor	 signaling	 pathway	 or	 the	
apoptosis	machinery	have	shown	efficacy	in	17p-	CLL,	with	a	better	treatment	response	and	longer	
progression-free	 survival	 [6-8].	 Despite	 good	 initial	 responses	 to	 these	 new	 targeted	 therapies,	
relapse	can	still	occur	-	particularly	in	patients	bearing	a	complex	karyotype	(K)	[9].	In	contrast,	some	
patients	with	de	novo	17p-	CLL	have	stable	disease	and	remain	asymptomatic	for	prolonged	periods	
of	time	[10,	11].	All	these	observations	underline	the	clinical	heterogeneity	of	17p-	CLL.	It	has	been	
shown	that	a	number	of	clinical	and	biological	markers	(such	as	 IGHV	mutational	status,	the	size	of	
the	 17p-	 clone,	 and	 genomic	 complexity)	 are	 significantly	 linked	 to	 the	 clinical	 outcome	 in	 the	
subgroup	of	patients	with	17p-	CLL	[12,	13].	
The	 objectives	 of	 the	 present	 study	 of	 a	 series	 of	 195	 patients	 with	 17p-	 CLL	 were	 to	 determine	
whether	(i)	the	type	of	chromosomal	abnormality	 leading	to	17p	 loss	(i.e.	translocations,	deletions,	
rings	 and	 isochromosomes,	 as	 identified	 by	 K	 analysis)	was	 associated	with	 the	 prognosis,	 and	 (ii)	
additional	aberrations	had	an	impact	on	the	clinical	outcome.	
	
Methods	
Patient	selection	
Databases	 from	 20	 French	 and	 Belgian	 institutions	were	 retrospectively	 screened	 for	 cases	with	 a	
morphological	 and	 immunological	 diagnosis	 of	 CLL	 according	 to	 the	 iwCLL	 criteria	 [14],	 in	 which	
informative	K	analysis	showed	a	loss	of	17p	and	FISH	confirmed	the	loss	of	the	TP53	gene.	A	total	of	
195	 patients	 were	 identified.	 The	 patients’	 clinical	 and	 biological	 characteristics	 were	 extracted	
retrospectively	from	medical	records.	The	study	was	performed	in	accordance	with	the	Declaration	
of	Helsinki,	and	was	approved	by	the	local	 investigational	review	board	(CPP-Ile-de-France	VI,	Paris,	
France;	date:	09/15/2011).	
Karyotype	and	FISH	analyses	
All	 the	 K	 results	 were	 reviewed	 by	 the	 members	 of	 the	 Groupe	 Francophone	 de	 Cytogénétique	
Hématologique	 and	 then	 classified	 according	 to	 the	 International	 System	 for	 Human	 Cytogenetic	
Nomenclature	(ISCN	2016).	Complex	Ks	were	defined	as	the	presence	of	three	or	more	numerical	or	
structural	chromosomal	abnormalities	(CK>3),	and	highly	complex	Ks	were	defined	as	the	presence	of	
five	 or	 more	 abnormalities	 (CK>5).	 Monosomal	 Ks	 were	 defined	 as	 the	 presence	 of	 2	 autosomal	
monosomies	or	1	monosomy	with	at	least	1	structural	abnormality.	Data	from	routine	FISH	analyses	
were	 available	 for	 some	 of	 patients:	 11q22	 (ATM)	 (n=158),	 13q14	 (n=118),	 centromere	 of	
chromosome	12	(n=102),	and	8q24	(MYC)	(n=12).	
TP53	mutations	and	functional	assays	
TP53	mutations	were	analyzed	by	(i)	Sanger	sequencing	of	exons	2	to	11	(n=17),	exons	4	to	10	(n=29)	
or	exons	4	to	9	(n=12),	or	(ii)	next-generation	sequencing	(NGS)	on	a	MiSeq®	platform	(Illumina,	San	
Diego,	 CA)	 using	 the	 CLL	 MASTR	 PLUS	 kit	 (Multiplicom,	 Niel,	 Belgium)	 (n=9)	 or	 on	 a	 Ion	 Torrent	
platform	 (Life	 Technologies,	 Carlsbad,	 CA)	 using	 the	 Ion	AmpliSeq™	TP53	Panel	 (Life	 Technologies)	
(n=8).	A	negative	result	with	Sanger	sequencing	was	not	considered	to	be	 informative	because	this	
technique	 does	 not	 cover	 all	 the	 exons	 and	 is	 not	 sensitive	 (10%).	 A	 functional	 assay	 of	 p53	was	
carried	out	as	described	previously	[15].	
Statistical	analysis	
Treatment-free	survival	(TFS)	and	OS	were	defined	as	the	time	interval	between	diagnosis	and	first-
line	treatment	or	death,	respectively,	or	(in	the	absence	of	these	events)	last	follow-up.	
Categorical	 variables	 were	 compared	 using	 the	 chi-squared	 test	 or	 Fisher’s	 exact	 test,	 while	
continuous	 variables	 were	 compared	 using	 the	 Mann-Whitney	 test.	 Survival	 analyses	 were	
performed	using	the	Kaplan-Meier	method.	The	log-rank	test	was	used	for	intergroup	comparisons	of	
OS	 or	 TFS	 curves.	 The	 variables	 analyzed	 were	 age	 (<65	 vs.	 >65),	 Binet	 stage	 (A	 vs.	 B/C),	 IGHV	
mutation	status,	the	percentage	of	cells	bearing	the	TP53	deletion	(<20%	vs.	>20%,	<	35%	vs.	>35%,	<	
80%	vs.	>80%),	occurrence	of	17p-	after	treatment,	the	number	of	17p	abnormalities	(1	vs	>2),	a	17p	
abnormality	alone	(according	to	the	K),	an	unbalanced	translocation	involving	17p	(U-translocation-
17p),	a	deletion	17p,	a	monosomy	17,	an	isochromosome	17q	[i(17q)],	a	der/dic(17;18)(q10;q10),	a	
CK	with	>3	or	>5	abnormalities,	a	monosomal	K,	U-translocations	(all:	17p	and	not	17p),	the	presence	
of	additional	U-translocations	(U-translocation-not	17p),	8q24	gain,	8p	deletion,	trisomy	12,	and	11q	
deletion.	Multivariate	analysis	(with	Cox	proportional	hazards	regression	models)	was	subsequently	
performed	 to	 assess	 the	 independent	 prognostic	 value	 of	 covariates	 that	 were	 significant	 in	 the	
univariate	 analysis.	 There	 were	 too	 few	 data	 on	 IGHV	 mutations	 for	 inclusion	 in	 the	multivariate	
analysis.	The	quality	of	the	multivariate	models	for	TFS	and	OS	was	confirmed	in	a	log-likelihood-ratio	
test	(p<0.0001).	The	prognostic	significance	of	each	variable	was	assessed	with	the	Wald	test.		
To	compare	survival	in	patients	in	whom	17p-	occurred	before	vs.	after	treatment,	the	time	interval	
between	the	first	documentation	of	17p-	and	death	or	last	follow-up	was	also	evaluated.		
All	tests	were	two-sided,	and	the	threshold	for	statistical	significance	was	set	to	p≤0.05.	All	statistical	
analyses	were	performed	using	MedCalc	software	(version	17.8.6,	MedCalc	Software	bvba,	Ostend,	
Belgium;	http://www.medcalc.org;	2017).	
	
Results	
	
Characteristics	of	the	study	population	
The	characteristics	of	the	195	 included	patients	(median	[range]	age	at	diagnosis:	63	[33-88]	years;	
males:	66%)	are	summarized	in	Table	I.	The	Binet	stage	at	diagnosis	was	A	in	100	patients	(59%),	B	in	
48	(29%),	and	C	in	21	(12%).	Data	on	IGHV	mutational	status	was	available	for	47	patients,	of	whom	
38	(81%)	did	not	bear	mutations.	The	median	[range]	time	since	after	diagnosis	was	70	months	[0-
401].	Most	of	 the	patients	with	 informative	data	had	been	 treated	 (158	out	of	182,	87%),	and	 the	
median	 number	 of	 treatments	 was	 2.5	 [0-10].	 In	 71	 patients,	 the	 time	 of	 occurrence	 of	 the	 17p-	
could	 not	 be	 determined	 because	 (i)	 cytogenetic	 analyses	 were	 not	 performed	 before	 treatment	
(n=58),	or	(ii)	data	on	treatment	were	missing	(n=13).	When	considering	the	remaining	124	patients,	
28	(23%)	did	not	present	with	17p-	at	diagnosis;	hence,	the	deletion	had	occurred	after	treatment	(a	
median	 of	 77.5	 months	 [22-291]	 after	 diagnosis).	 In	 96	 of	 the	 124	 patients	 (77%,	 including	 24	
patients	 not	 having	 been	 treated	 at	 last	 follow-up),	 the	 17p-	 was	 present	 before	 treatment;	 the	
median	time	interval	between	diagnosis	and	first	detection	of	17p-	was	1	month	[0-291].	The	TP53	
gene	 was	 mutated	 in	 55	 of	 the	 60	 (92%)	 patients	 with	 informative	 data.	 The	 protein	 p53	 was	
dysfunctional	in	all	42	cases	tested,	including	2	patients	in	whom	a	TP53	mutation	was	not	detected	
by	NGS.	
Karyotyping	and	FISH	data	
Karyotyping	and	FISH	results	are	summarized	in	Table	II.	According	to	K,	the	median	[range]	number	
of	 chromosomal	 abnormalities	 (including	17p-)	was	4	 ([1-26];	 a	CK>3	was	 found	 in	141	of	 the	195	
(72%)	 patients,	 including	 89	 (46%)	 with	 a	 highly	 CK>5.	 The	 K	 was	 monosomal	 in	 52	 of	 the	 195	
patients	 (27%).	 A	 large	 majority	 of	 patients	 (181	 out	 of	 195,	 93%)	 displayed	 one	 or	 more	 U-
translocation(s);	 some	 involved	 17p,	 and	 others	 did	 not.	 The	 presence	 of	 U-translocations	 was	
strongly	 associated	 with	 CK>3	 (78%	 vs.	 0%	 in	 patients	 with	 and	 without	 U-translocations,	
respectively;	 p<0.0001)	 and	 CK>5	 (49%	 vs.	 0%,	 respectively;	 p=0.0001).	 A	 total	 of	 240	 17p	
abnormalities	were	found	in	the	195	patients:	162	(83%)	of	these	patients	had	one	17p	abnormality,	
25	(13%)	had	two	independent	17p	abnormalities,	and	8	(4%)	had	three	or	more	17p	abnormalities.	
The	 17p-	 was	 the	 sole	 abnormality	 detected	 by	 K	 in	 28	 of	 the	 195	 (14%)	 cases.	 When	 other	
abnormalities	were	also	present,	the	17p-	was	in	the	primary	clone	in	43	of	the	195	(26%)	patients,	in	
a	sub-clone	in	42	(25%),	in	the	same	clone	as	the	other	aberrations	in	64	(38%),	or	in	an	independent	
clone	in	18	(11%).	In	the	majority	of	cases,	loss	of	17p	resulted	from	a	U-translocation	involving	17p	
(-17p)	and	various	chromosome	partners	 (Supplemental	Figure	1).	A	total	of	167	U-translocations(-
17p)	 were	 found	 in	 158	 of	 the	 195	 patients	 (81%).	 The	 partner	 was	 not	 identified	 in	 35	 cases	
[add(17p)].	Of	the	132	translocations	with	an	identified	partner,	68	were	arm-to-arm	translocations;	
32	of	the	 latter	 involving	the	 long	arm	of	the	chromosome	18.	 In	7	of	these	32	cases,	the	dicentric	
nature	 of	 the	 derivative	 chromosome	 dic(17;18)(p11;p11)	 was	 proven	 by	 FISH	 with	 centromere	
probes.	 According	 to	 the	 ISCN	 nomenclature,	 the	 other	 cases	 were	 der(17;18)(q10;q10).	 Overall,	
der/dic(17;18)	was	the	most	frequent	U-translocation(-17p)	because	it	was	present	in	32	of	the	195	
patients	 (16%).	 The	 other	 frequent	 arm-to-arm	 translocations	 involved	 chromosomes	 8q	 (n=11,	
resulting	 in	 8p	 deletion),	 14q	 (n=6),	 4q	 (n=4),	 13q	 (n=4),	 and	 21q	 (n=4).	 The	 remaining	 64	 U-
translocations(-17p)	 (not	 arm-to-arm)	 involved	 a	 wider	 variety	 of	 partners	 -	 most	 frequently	
chromosome	8	(n=15);	this	led	to	del8p	(n=6),	gain8q	(n=6),	or	del8q	(n=3)	(Supplemental	Figure	1B).	
The	other	17p	abnormalities	were	17p	deletion	 (n=45	out	of	195,	23%),	monosomy	17	 (n=15,	8%),	
i(17q)	 (n=9,	 5%)	 and	 ring	 chromosome	17	 (n=4,	 2%)	 (Table	 II	 and	 Supplemental	 Figure	 1A).	 Lastly,	
FISH	 showed	 that	 the	percentage	of	 cells	with	 a	TP53	 deletion	 ranged	 from	3%	 to	 100%	 (median:	
70%).	
When	considering	the	additional	abnormalities	associated	with	17p-,	U-translocations(-not	17p)	were	
found	 in	121	of	 the	195	patients	 (63%).	The	presence	of	U-translocations(-not	17p)	was	associated	
with	 CK>3	 (95%	 vs.	 35%	 in	 patients	 with	 and	 without	 U-translocations(-not	 17p),	 respectively;	
p<0.0001)	and	CK>5	(68%	vs.	9%,	respectively;	p<0.0001).	After	combination	of	the	K	and	available	
FISH	findings,	13q14	deletion	was	detected	in	71	of	the	118	documented	cases	(60%),	8p	deletion	in	
40	out	of	189	cases	(21%),	trisomy	12	in	30	out	of	195	cases	(15%),	8q24	gain	in	14	out	of	112	cases	
(12.5%),	and	11q	deletion	(ATM	gene)	in	20	out	of	161	cases	(12%).	
	
Treatment-free	and	overall	survival	
Treatment-free	survival	was	studied	for	the	96	patients	in	whom	17p	was	present	before	treatment.	
The	 median	 TFS	 time	 was	 18	 months.	 In	 a	 univariate	 analysis,	 the	 parameters	 associated	 with	
significantly	 shorter	 TFS	 were	 Binet	 stage	 B/C	 (hazard	 ratio	 (HR)=6.24,	 p<0.0001),	 monosomy	 17	
(HR=2.07,	p=0.04),	a	high	CK	(HR=1.81,	p=0.009)	and	8q24	gain	(HR=6.46,	p<0.0001).	In	a	multivariate	
analysis,	stage	B/C	and	8q24	gain	remained	significantly	associated	with	shorter	TFS	(Table	III).	
For	 the	 study	 population	 as	 a	 whole,	 the	 median	 OS	 time	 from	 diagnosis	 was	 179	 months.	 In	 a	
univariate	 analysis,	 we	 found	 that	 age	 >65,	 Binet	 stage	 B/C,	 or	 unmutated	 IGHV	 status	 were	
associated	with	a	significantly	shorter	median	OS	time	(Table	III,	Supplemental	Figure	2).	There	were	
no	significant	statistical	differences	in	the	impact	on	OS	between	the	different	abnormalities	leading	
to	 loss	 of	 17p,	 i.e.	U-translocations(-17p),	 der/dic(17;18),	monosomy	17	 or	 deletion	 17p.	 Likewise,	
the	 number	 of	 17p-	 abnormalities	 and	 the	 percentage	 of	 cells	 harboring	 the	 delTP53	 (whether	
dichotomized	 or	 not)	 were	 not	 significant	 factors.	 The	 presence	 of	 an	 i(17q)	 was	 correlated	 with	
trisomy	12	(44%	vs.	14%	in	patients	with	or	without	i(17q),	respectively;	p=0.03),	a	higher	percentage	
of	tumor	cells	with	delTP53	(a	median	of	88%	vs.	60%	in	patients	with	or	without	i(17q),	respectively;	
p=0.003),	 and	 a	 shorter	 OS	 (69	 vs.	 179	 months	 in	 patients	 with	 or	 without	 i(17q),	 respectively;	
p=0,04)	 (Figure	 1).	 Analysis	 of	 the	 impact	 of	 the	 other	 cytogenetic	 aberrations	 revealed	 that	 the	
presence	of	U-translocations(-not	17p)	was	associated	with	a	shorter	OS	time	(153	vs.	223	months	in	
patients	with	or	without	U-translocations(-not	17p),	respectively;	p=0.03).	When	taking	account	of	all	
the	 U-translocations	 (i.e.	 17p	 and	 not	 17p),	 a	 shorter	 OS	was	 also	 observed	 in	 the	 group	with	 U-
translocations	 (171	months	 vs.	median	 not	 reached,	 p=0.04).	 Lastly,	 the	 presence	 of	 an	 8q24	 gain	
strongly	impacted	the	OS	(HR=3.48,	p=0.001)	(Figure	1).	In	a	multivariate	analysis,	age	>	65	(HR=2.65,	
p=0.03),	Binet	stage	B/C	(HR=10.01,	p<0.0001)	and	8q24	gain	(HR=3.73,	p=0.01)	were	independently	
and	significantly	associated	with	poor	OS	(Table	III).	
When	comparing	the	survival	time	after	the	first	documentation	of	17p-,	the	patients	who	acquired	
this	 abnormality	 after	 treatment	 had	 a	 shorter	 OS	 time	 than	 those	 presenting	 with	 17p-	 prior	 to	
treatment	(HR=2.02,	p=0.03)	(Supplemental	Figure	3).	
	
	
Discussion	
To	the	best	of	our	knowledge,	the	present	study	of	195	CLL	patients	with	17p-	is	the	largest	cohort	in	
which	the	clinical	significance	of	chromosome	17p	abnormalities	has	been	assessed	in	detail.	In	line	
with	 the	 literature	 data,	we	 found	 that	 loss	 of	 the	 short	 arm	of	 chromosome	 17	 is	mainly	 due	 to	
unbalanced	 translocations	 (in	 70%	 of	 cases),	 rather	 than	 17p	 deletion,	 an	 isochromosome	 17q	 or	
monosomy	 17	 [3,	 16].	 Most	 of	 the	 U-translocations(-17p)	 (52%)	 were	 arm-to-arm	 events.	 In	 the	
remaining	U-translocations(-17p),	 the	breakpoints	were	mainly	 located	 in	17p11	or	p12.	 In	general	
(and	 regardless	 of	 the	 type	 of	 17p	 abnormality),	 all	 or	 almost	 all	 of	 the	 17p	 arm	 was	 lost.	 This	
supports	 the	 recent	 hypothesis	 whereby	 the	 effects	 of	 17p	 deletion	 on	 tumor	 progression	 and	
treatment	resistance	might	involve	several	genes	and	might	not	be	solely	due	to	TP53	loss	[17].	
The	most	frequent	U-translocation(-17p)	was	dic/der(17;18),	since	it	accounted	for	16%	of	the	study	
population.	Woyach	et	al.	suggested	that	dic(17;18)	may	correspond	to	the	most	aggressive	subset	of	
17p-	 CLL	 cases	 [18].	 We	 could	 not	 confirm	 this	 hypothesis;	 when	 compared	 with	 the	 other	
chromosomal	 abnormalities	 involving	 17p	 in	 our	 large	 series,	 dic(17;18)	 did	 not	 have	 a	 significant	
impact	on	outcome.	
In	a	univariate	analysis,	we	found	that	monosomy	17	was	significantly	associated	with	a	shorter	TFS	
(relative	to	the	other	17p	abnormalities),	and	that	 isochromosome	17q	was	significantly	associated	
with	a	shorter	OS.	 Isochromosome	17q	has	been	described	as	a	frequent	aberration	(up	to	33%)	 in	
small	series	of	CLL	cases	with	a	TP53	deletion	[3,	19].	A	much	lower	incidence	(4%)	was	observed	in	
the	present	study.	Moreover,	i(17q)	was	significantly	associated	with	trisomy	12	(44%,	p=0.03)	and	a	
larger	 clone	 17p-	 size.	 In	 a	 recent	 study,	 CLL	 patients	with	 i(17q)	 tended	 to	 have	 poorer	 OS	 than	
patients	with	other	 anomalies	 affecting	 17p13	–	 even	 though	 all	 the	 tested	 individuals	were	 IGHV	
mutated	[20].	In	the	present	series,	the	IGHV	genes	were	sequenced	in	only	2	of	the	9	patients	with	
i(17q);	neither	carried	IGHV	mutations.	This	finding	shows	that	mutated	IGHV	status	is	not	a	constant	
feature	in	cases	of	i(17q).	The	present	results	corroborated	the	association	between	i(17q)	status	and	
a	poor	outcome	because	this	defect	was	significantly	correlated	with	shorter	OS	(p=0.04).	However,	
further	studies	are	needed	to	establish	whether	i(17q)	is	an	independent	prognostic	marker	in	17p-	
CLL.	
In	accordance	with	previous	reports	[12,	21,	22],	we	observed	a	shorter	OS	(calculated	following	the	
first	documentation	of	17p-)	in	patients	having	acquired	the	17p-	after	treatment	than	in	those	with	
17p-	present	before	treatment.	This	finding	might	simply	reflect	the	fact	that	patients	with	acquired	
17p-	have	more	advanced	disease	but	may	also	suggest	that	treatment	selected	a	more	aggressive	
clone	with	a	growth	advantage.	
In	contrast	 to	other	series,	we	did	not	observe	a	significant	association	between	the	percentage	of	
cells	with	TP53	deletion	and	the	clinical	outcomes.	In	the	literature,	it	has	been	reported	that	a	low	
percentage	of	17p-	cells	is	associated	with	a	more	favorable	outcome.	However,	the	optimal	cut-off	
varied	markedly	from	one	study	to	another	(from	10%	to	80%)	[10,	12,	23,	24]	-	indicating	that	this	
parameter	is	cohort-dependent	and	should	not	be	taken	into	account	when	evaluating	the	prognosis	
of	patients	with	CLL.	Furthermore,	several	reports	have	documented	the	impact	of	small	clones	with	
disrupted	TP53	genes	on	disease	progression	[25,	26].	
Although	 only	 a	 small	 proportion	 of	 17p-	 patients	 were	 analyzed,	 we	 found	 that	 all	 the	 tested	
individuals	 had	 a	 dysfunctional	 p53	 protein	 (including	 2	 cases	 without	 a	 TP53	 mutation).	 These	
results	highlight	the	 importance	of	continuing	to	screen	for	17p	 loss	on	a	routine	basis.	FISH	 is	still	
the	best	 technique	for	detecting	TP53	deletion;	 its	sensitivity	 threshold	of	about	5%	 is	much	 lower	
than	 that	 obtained	with	 innovative	 tools	 such	 as	 single	 nucleotide	polymorphism	arrays,	multiplex	
ligation-dependent	probe	amplification	and	massively	parallel	sequencing.	
We	also	looked	at	whether	additional	chromosomal	abnormalities	could	influence	the	outcome.	We	
confirm	that	a	complex	K	 is	very	frequent	 in	17p-	CLL,	since	 it	was	detected	 in	72%	of	our	patients	
[12,	 24,	 27].	 Karyotype	 complexity	 is	 a	 recently	 discovered	 factor	 for	 a	 poor	 prognosis	 in	 CLL	 in	
general	 [4,	 28,	 29]	 and	 in	 the	 17p-	 subset	 [24,	 30].	 In	 the	 literature,	 the	 cut-off	 used	 to	 define	 a	
complex	K	varies	from	3	to	5	abnormalities	[4,	31].	In	our	series,	a	highly	CK	(>5	abnormalities)	was	
associated	 with	 worse	 TFS,	 whereas	 a	 CK	 (>3	 abnormalities)	 had	 no	 clinical	 impact.	 This	 finding	
suggests	that	a	cut-off	of	5	abnormalities	is	more	suitable	for	identifying	17p-	CLL	patients	with	the	
most	 aggressive	 disease.	 Previous	 studies	 of	 unselected	 CLL	 patients	 have	 described	 the	 poor	
prognosis	 of	 unbalanced	 translocations	 [4,	 27,	 30,	 32,	 33].	 Our	 present	 results	 showed	 that	 U-
translocations	 are	 also	 associated	 with	 shorter	 OS	 in	 the	 17p-	 CLL	 subset.	 Regarding	 the	 classical	
abnormalities	detected	by	FISH	in	CLL	(such	as	tri12,	del13q	and	del11q),	we	were	surprised	to	find	
the	same	frequency	of	 these	aberrations	 in	 the	17p-	subset	as	 in	 the	whole	population	of	patients	
with	 CLL	 [1].	 This	 suggests	 that	 17p-	 appears	 independently,	 and	 that	 none	 of	 the	 other	
abnormalities	promotes	its	occurrence.	However,	i(17q)	-	correlated	with	trisomy	12	-	appears	to	be	
an	exception.		
The	 8q24	 gain	 (encompassing	 the	MYC	 gene)	 is	 detected	 with	microarrays	 in	 3-4%	 of	 the	 overall	
population	of	patients	with	CLL,	and	is	independently	associated	with	shorter	OS	and/or	shorter	time	
to	 first	 treatment	 [34-36].	 In	 the	 literature,	 the	 frequency	 of	 8q24	 gain	 is	 higher	 in	 the	 17p-	 CLL	
subset	and	ranges	from	9%	to	44%	[13,	24,	35-37].	In	the	present	large	series,	we	found	an	8q24	gain	
in	12.5%	of	patients.	Furthermore,	we	demonstrated	that	8q24	gain	is	a	strong,	predictive	marker	of	
poor	 outcome	 within	 the	 17p-	 CLL	 subgroup,	 and	 has	 independent	 prognostic	 value	 for	 OS.	 This	
observation	 suggests	 that	 TP53	 deletion	 and	MYC	 gain	 act	 in	 synergy;	 the	 outcome	 is	 particularly	
dismal	when	both	are	present.	Indeed,	the	occurrence	of	both	alterations	may	represent	a	"double-
hit"	CLL	 that	 is	 reminiscent	of	 the	aggressive,	 "double-hit",	high-grade	B-cell	 lymphomas	harboring	
rearrangements	 of	 MYC	 and	 BCL2	 or	 BCL6	 [38].	 It	 is	 noteworthy	 that	 we	 did	 not	 observe	 any	
translocation	involving	MYC	in	the	present	series.	Given	the	high	frequency	of	genomic	complexity	in	
these	patients,	8q24	gain	can	be	missed	by	karyotyping.	In	order	to	validate	the	clinical	significance	
of	 this	 aberration,	 17p-	 CLL	 patients	 enrolled	 in	 prospective	 clinical	 trials	 should	 be	 systematically	
screened	by	FISH	analysis	using	a	MYC	probe.	
	
In	 conclusion,	 our	 data	 show	 that	 patients	with	 17p-	 CLL	 often	 present	 CK	 (>3	 abnormalities)	 and	
highly	 CK	 (>5	 abnormalities),	 unbalanced	 translocations,	 8q24	 gain,	 and	 unmutated	 IGHV.	 The	
various	abnormalities	 leading	 to	 loss	of	17p	do	not	have	all	 the	 same	clinical	 significance:	 i(17q)	 is	
associated	with	a	shorter	OS	than	the	other	17p	aberrations.	Furthermore,	the	presence	of	additional	
unbalanced	 translocations	aggravates	 the	outcome.	Our	 results	highlight	 the	value	of	 conventional	
karyotyping	 for	 identifying	 alterations	 that	 modulate	 the	 prognosis	 in	 this	 aggressive	 subset	 of	
patients.	 Lastly,	 8q24	 gain	 is	 a	 strong,	 independent	 factor	 for	 poor	 survival;	 systematic,	 targeted	
screening	for	this	abnormality	should	be	considered	with	a	view	to	better	defining	the	prognosis	of	
patients	with	17p-	CLL	and	identifying	the	very	high-risk	“double-hit”	subgroup.	
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Legends	to	figures	
Figure	1	
Overall	 survival	 in	 the	 whole	 study	 population,	 according	 to	 the	 presence	 or	 absence	 of	
isochromosome	17q	[i(17q)]	(A),	unbalanced	translocations	(U-translocations)	(all,	including	17p)	(B),	
additional	U-translocations	to	17p-	(C),	and	8q24	gain	(D).	
	
	
	 	
References	
1.	 Dohner	 H,	 Stilgenbauer	 S,	 Benner	 A,	 et	 al.	 Genomic	 aberrations	 and	 survival	 in	 chronic	
lymphocytic	leukemia.	The	New	England	journal	of	medicine	2000;343:1910-1916.	
2.	 Hallek	 M,	 Fischer	 K,	 Fingerle-Rowson	 G,	 et	 al.	 Addition	 of	 rituximab	 to	 fludarabine	 and	
cyclophosphamide	in	patients	with	chronic	lymphocytic	leukaemia:	a	randomised,	open-label,	phase	
3	trial.	Lancet	2010;376:1164-1174.	
3.	 Fink	 SR,	 Smoley	 SA,	 Stockero	 KJ,	 et	 al.	 Loss	 of	 TP53	 is	 due	 to	 rearrangements	 involving	
chromosome	region	17p10	approximately	p12	in	chronic	lymphocytic	leukemia.	Cancer	genetics	and	
cytogenetics	2006;167:177-181.	
4.	 Baliakas	P,	Iskas	M,	Gardiner	A,	et	al.	Chromosomal	translocations	and	karyotype	complexity	
in	 chronic	 lymphocytic	 leukemia:	 a	 systematic	 reappraisal	 of	 classic	 cytogenetic	 data.	 American	
journal	of	hematology	2014;89:249-255.	
5.	 Ouillette	 P,	 Collins	 R,	 Shakhan	 S,	 et	 al.	 Acquired	 genomic	 copy	 number	 aberrations	 and	
survival	in	chronic	lymphocytic	leukemia.	Blood	2011;118:3051-3061.	
6.	 Furman	 RR,	 Sharman	 JP,	 Coutre	 SE,	 et	 al.	 Idelalisib	 and	 rituximab	 in	 relapsed	 chronic	
lymphocytic	leukemia.	The	New	England	journal	of	medicine	2014;370:997-1007.	
7.	 Farooqui	MZ,	 Valdez	 J,	 Martyr	 S,	 et	 al.	 Ibrutinib	 for	 previously	 untreated	 and	 relapsed	 or	
refractory	 chronic	 lymphocytic	 leukaemia	 with	 TP53	 aberrations:	 a	 phase	 2,	 single-arm	 trial.	 The	
Lancet	Oncology	2015;16:169-176.	
8.	 Stilgenbauer	 S,	 Eichhorst	 B,	 Schetelig	 J,	 et	 al.	 Venetoclax	 in	 relapsed	 or	 refractory	 chronic	
lymphocytic	 leukaemia	 with	 17p	 deletion:	 a	 multicentre,	 open-label,	 phase	 2	 study.	 The	 Lancet	
Oncology	2016;17:768-778.	
9.	 Thompson	PA,	O'Brien	SM,	Wierda	WG,	et	al.	Complex	karyotype	is	a	stronger	predictor	than	
del(17p)	 for	 an	 inferior	 outcome	 in	 relapsed	 or	 refractory	 chronic	 lymphocytic	 leukemia	 patients	
treated	with	ibrutinib-based	regimens.	Cancer	2015;121:3612-3621.	
10.	 Tam	 CS,	 Shanafelt	 TD,	 Wierda	 WG,	 et	 al.	 De	 novo	 deletion	 17p13.1	 chronic	 lymphocytic	
leukemia	 shows	 significant	 clinical	heterogeneity:	 the	M.	D.	Anderson	and	Mayo	Clinic	experience.	
Blood	2009;114:957-964.	
11.	 Best	 OG,	 Gardiner	 AC,	 Davis	 ZA,	 et	 al.	 A	 subset	 of	 Binet	 stage	 A	 CLL	 patients	 with	 TP53	
abnormalities	and	mutated	IGHV	genes	have	stable	disease.	Leukemia	2009;23:212-214.	
12.	 Delgado	J,	Espinet	B,	Oliveira	AC,	et	al.	Chronic	 lymphocytic	 leukaemia	with	17p	deletion:	a	
retrospective	 analysis	 of	 prognostic	 factors	 and	 therapy	 results.	 British	 journal	 of	 haematology	
2012;157:67-74.	
13.	 Delgado	J,	Salaverria	I,	Baumann	T,	et	al.	Genomic	complexity	and	IGHV	mutational	status	are	
key	 predictors	 of	 outcome	 of	 chronic	 lymphocytic	 leukemia	 patients	 with	 TP53	 disruption.	
Haematologica	2014;99:e231-234.	
14.	 Hallek	M,	Cheson	BD,	Catovsky	D,	et	al.	Guidelines	for	the	diagnosis	and	treatment	of	chronic	
lymphocytic	leukemia:	a	report	from	the	International	Workshop	on	Chronic	Lymphocytic	Leukemia	
updating	the	National	Cancer	Institute-Working	Group	1996	guidelines.	Blood	2008;111:5446-5456.	
15.	 Le	Garff-Tavernier	M,	Blons	H,	Nguyen-Khac	F,	et	al.	Functional	assessment	of	p53	in	chronic	
lymphocytic	leukemia.	Blood	cancer	journal	2011;1:e5.	
16.	 Callet-Bauchu	 E,	 Salles	 G,	 Gazzo	 S,	 et	 al.	 Translocations	 involving	 the	 short	 arm	 of	
chromosome	17	 in	 chronic	B-lymphoid	disorders:	 frequent	occurrence	of	dicentric	 rearrangements	
and	possible	association	with	adverse	outcome.	Leukemia	1999;13:460-468.	
17.	 Liu	Y,	Chen	C,	Xu	Z,	et	al.	Deletions	linked	to	TP53	loss	drive	cancer	through	p53-independent	
mechanisms.	Nature	2016;531:471-475.	
18.	 Woyach	JA,	Heerema	NA,	Zhao	J,	et	al.	Dic(17;18)(p11.2;p11.2)	is	a	recurring	abnormality	in	
chronic	 lymphocytic	 leukaemia	 associated	 with	 aggressive	 disease.	 British	 journal	 of	 haematology	
2010;148:754-759.	
19.	 Alhourani	E,	Rincic	M,	Melo	JB,	et	al.	Isochromosome	17q	in	Chronic	Lymphocytic	Leukemia.	
Leukemia	research	and	treatment	2015;2015:489592.	
20.	 Collado	 R,	 Puiggros	 A,	 Lopez-Guerrero	 JA,	 et	 al.	 Chronic	 lymphocytic	 leukemia	 with	
isochromosome	 17q:	 An	 aggressive	 subgroup	 associated	 with	 TP53	 mutations	 and	 complex	
karyotypes.	Cancer	letters	2017.	
21.	 Shanafelt	TD,	Witzig	TE,	Fink	SR,	et	al.	Prospective	evaluation	of	clonal	evolution	during	long-
term	 follow-up	 of	 patients	 with	 untreated	 early-stage	 chronic	 lymphocytic	 leukemia.	 Journal	 of	
clinical	oncology	:	official	journal	of	the	American	Society	of	Clinical	Oncology	2006;24:4634-4641.	
22.	 Stilgenbauer	S,	Sander	S,	Bullinger	L,	et	al.	Clonal	evolution	in	chronic	lymphocytic	leukemia:	
acquisition	 of	 high-risk	 genomic	 aberrations	 associated	with	 unmutated	VH,	 resistance	 to	 therapy,	
and	short	survival.	Haematologica	2007;92:1242-1245.	
23.	 Oscier	D,	Wade	R,	Davis	Z,	et	al.	Prognostic	factors	identified	three	risk	groups	in	the	LRF	CLL4	
trial,	independent	of	treatment	allocation.	Haematologica	2010;95:1705-1712.	
24.	 Blanco	 G,	 Puiggros	 A,	 Baliakas	 P,	 et	 al.	 Karyotypic	 complexity	 rather	 than	 chromosome	 8	
abnormalities	 aggravates	 the	 outcome	 of	 chronic	 lymphocytic	 leukemia	 patients	 with	 TP53	
aberrations.	Oncotarget	2016;7:80916-80924.	
25.	 Landau	 DA,	 Carter	 SL,	 Getz	 G,	 et	 al.	 Clonal	 evolution	 in	 hematological	 malignancies	 and	
therapeutic	implications.	Leukemia	2014;28:34-43.	
26.	 Nadeu	F,	Delgado	J,	Royo	C,	et	al.	Clinical	impact	of	clonal	and	subclonal	TP53,	SF3B1,	BIRC3,	
NOTCH1,	and	ATM	mutations	in	chronic	lymphocytic	leukemia.	Blood	2016;127:2122-2130.	
27.	 Haferlach	C,	Dicker	 F,	 Schnittger	 S,	 et	 al.	 Comprehensive	 genetic	 characterization	of	 CLL:	 a	
study	on	506	cases	analysed	with	chromosome	banding	analysis,	 interphase	FISH,	IgV(H)	status	and	
immunophenotyping.	Leukemia	2007;21:2442-2451.	
28.	 Le	Bris	Y,	Struski	S,	Guieze	R,	et	al.	Major	prognostic	value	of	complex	karyotype	in	addition	
to	 TP53	 and	 IGHV	 mutational	 status	 in	 first-line	 chronic	 lymphocytic	 leukemia.	 Hematological	
oncology	2016.	
29.	 Rigolin	GM,	Cavallari	M,	Quaglia	FM,	et	al.	In	CLL,	comorbidities	and	the	complex	karyotype	
are	associated	with	an	inferior	outcome	independently	of	CLL-IPI.	Blood	2017;129:3495-3498.	
30.	 Herling	 CD,	 Klaumunzer	 M,	 Rocha	 CK,	 et	 al.	 Complex	 karyotypes	 and	 KRAS	 and	 POT1	
mutations	impact	outcome	in	CLL	after	chlorambucil-based	chemotherapy	or	chemoimmunotherapy.	
Blood	2016;128:395-404.	
31.	 Jaglowski	 SM,	 Ruppert	 AS,	 Heerema	 NA,	 et	 al.	 Complex	 karyotype	 predicts	 for	 inferior	
outcomes	 following	 reduced-intensity	 conditioning	 allogeneic	 transplant	 for	 chronic	 lymphocytic	
leukaemia.	British	journal	of	haematology	2012;159:82-87.	
32.	 Mayr	C,	Speicher	MR,	Kofler	DM,	et	al.	Chromosomal	translocations	are	associated	with	poor	
prognosis	in	chronic	lymphocytic	leukemia.	Blood	2006;107:742-751.	
33.	 Van	 Den	 Neste	 E,	 Robin	 V,	 Francart	 J,	 et	 al.	 Chromosomal	 translocations	 independently	
predict	 treatment	 failure,	 treatment-free	 survival	 and	overall	 survival	 in	B-cell	 chronic	 lymphocytic	
leukemia	patients	treated	with	cladribine.	Leukemia	2007;21:1715-1722.	
34.	 Brown	JR,	Hanna	M,	Tesar	B,	et	al.	Integrative	genomic	analysis	implicates	gain	of	PIK3CA	at	
3q26	and	MYC	at	8q24	in	chronic	lymphocytic	leukemia.	Clinical	cancer	research	:	an	official	journal	
of	the	American	Association	for	Cancer	Research	2012;18:3791-3802.	
35.	 Rinaldi	A,	Mian	M,	Kwee	I,	et	al.	Genome-wide	DNA	profiling	better	defines	the	prognosis	of	
chronic	lymphocytic	leukaemia.	British	journal	of	haematology	2011;154:590-599.	
36.	 Houldsworth	 J,	Guttapalli	A,	Thodima	V,	et	al.	Genomic	 imbalance	defines	 three	prognostic	
groups	 for	 risk	 stratification	of	patients	with	chronic	 lymphocytic	 leukemia.	Leukemia	&	 lymphoma	
2014;55:920-928.	
37.	 Forconi	F,	Rinaldi	A,	Kwee	I,	et	al.	Genome-wide	DNA	analysis	identifies	recurrent	imbalances	
predicting	 outcome	 in	 chronic	 lymphocytic	 leukaemia	 with	 17p	 deletion.	 British	 journal	 of	
haematology	2008;143:532-536.	
38.	 Aukema	 SM,	 Siebert	 R,	 Schuuring	 E,	 et	 al.	 Double-hit	 B-cell	 lymphomas.	 Blood	
2011;117:2319-2331.	
	
